



Targeted Therapy

		Clinical Proof of Concept	Pivotal	Marketed
Jakafi® (ruxolitinib)¹ JAK1/JAK2	Myelofibrosis ² , polycythemia vera ³ , acute graft-versus-host disease (GVHD) ⁴			U.S.
Pemazyre® (pemigatinib) FGFR1/2/3	Cholangiocarcinoma ⁵			U.S.
Monjuvi® (tafasitamab-cxix)^{6,7} CD19	Diffuse large B-cell lymphoma ⁸			U.S.
Iclusig® (ponatinib)⁹ BCR-ABL	Chronic myeloid leukemia ¹⁰ , Ph+ acute lymphoblastic leukemia ¹¹			EUROPE
ruxolitinib¹² JAK1/JAK2	Chronic GVHD, COVID-19 associated cytokine storm			
ruxolitinib + piasclisib JAK1/JAK2, PI3Kδ	Myelofibrosis			
itacitinib JAK1	Chronic GVHD			
pemigatinib FGFR1/2/3	Bladder cancer, solid tumors, 8p11 myeloproliferative neoplasms			
piasclisib PI3Kδ	Follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma			
INCB57643 BET	Myelofibrosis			
INCB00928 ALK2	Myeloproliferative disorders			
tafasitamab⁷ CD19	Chronic lymphocytic leukemia			

Inflammation/Autoimmunity

ruxolitinib cream JAK1/JAK2	Atopic dermatitis, vitiligo			
INCB00928 ALK2	Fibrodysplasia ossificans progressiva			
INCB54707 JAK1	Hidradenitis suppurativa			
piasclisib PI3Kδ	Autoimmune hemolytic anemia			

Immuno-Oncology

		Clinical Proof of Concept	Pivotal	Marketed
retifanlimab¹³ PD-1	Squamous cell anal carcinoma, non-small cell lung cancer (NSCLC)			
retifanlimab¹³ PD-1	MSI-H endometrial cancer, Merkel cell carcinoma			
INCB86550 PD-L1	Solid tumors			
MCLA-145¹⁴ PD-L1xCD137	Solid tumors			
epacadostat IDO1	Multiple tumor types			
INCB01158¹⁵ ARG	Multiple tumor types			
INCAGN1876¹⁶ GITR	Solid tumors			
INCAGN1949¹⁶ OX40	Solid tumors			
INCAGN2390¹⁶ TIM-3	Solid tumors			
INCAGN2385¹⁶ LAG-3	Multiple tumor types			
INCB81776 AXL/MER	Multiple tumor types			

Partnered

Olumiant® (baricitinib)¹⁷ JAK1/JAK2	Rheumatoid arthritis ¹⁸			
Tabrecta™ (capmatinib)¹⁹ MET	NSCLC with METex14 ²⁰			
baricitinib¹⁷ JAK1/JAK2	Atopic dermatitis, systemic lupus erythematosus, alopecia areata, COVID-19			
capmatinib¹⁹ MET	Liver cancer			

Updated as of August 4, 2020

1. Jakafi marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis ex-U.S. 2. Adults with intermediate or high-risk myelofibrosis 3. Adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 4. Adults and pediatric patients 12 years and older with steroid-refractory acute GVHD 5. Adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test 6. Co-commercialization in the U.S. with MorphoSys 7. Development in collaboration with MorphoSys 8. In combination with lenalidomide in adults with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant 9. European rights to Iclusig licensed from ARIAD 10. Adults with chronic phase, accelerated phase, or blast phase CML who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation 11. Adults with Ph+ ALL who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation 12. Certain development programs conducted in collaboration with Novartis 13. In collaboration with MacroGenics 14. In collaboration with Merus 15. Co-development with Calithera 16. Discovery collaboration with Agenus 17. Worldwide rights to baricitinib licensed to Lilly 18. Approved in multiple territories globally for certain patients with moderate to severe rheumatoid arthritis 19. Worldwide rights to capmatinib licensed to Novartis 20. Approved in the U.S. and Japan for certain patients with NSCLC with MET exon 14 skipping (METex14) mutation

The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.

[Summary of Product Characteristics for Iclusig® \(ponatinib\)](#)